<DOC>
	<DOCNO>NCT02649790</DOCNO>
	<brief_summary>This first-in-human , multi-center , open-label clinical study separate dose escalation ( Phase 1 ) expansion ( Phase 2 ) stage assess preliminary safety , tolerability , efficacy second generation oral XPO1 inhibitor KPT-8602 patient relapsed/refractory MM .</brief_summary>
	<brief_title>Study Safety , Tolerability Efficacy KPT-8602 Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Inclusion Criteria Evidence disease progression : Symptomatic relapse refractory require current treatment . Previously treat ≥ 3 prior regimen ( line therapy ) include least one following : alkylating agent , immunomodulatory drug , proteasome inhibitor , steroid . Must refractory recent anticancer regimen . Must measurable disease define one following : Serum Mprotein ≥ 0.5 g/dL serum protein electrophoresis ( SPEP ) IgA myeloma , quantitative IgA . If SPEP felt unreliable routine Mprotein measurement ( e.g. , patient IgA MM ) , quantitative Ig level nephelometry turbidometry acceptable ; Urinary Mprotein excretion least 200 mg/24 hour ; Serum Free Light Chain ( Serum FLC ) whereby involve light chain measure ≥ 10 mg/dL abnormal ratio . Eastern Cooperative Oncology Group performance status ≤ 1 . Exclusion Criteria Time since last prior therapy : Radiation , chemotherapy , immunotherapy anticancer therapy , include investigational anticancer therapy ≤ 2 week prior Cycle 1 Day 1 . Palliative steroid disease relate symptom allow 3 day prior Cycle 1 Day 1 . Active graft versus host disease allogeneic stem cell transplantation . At least 3 month must elapse since completion allogeneic stem cell transplantation . Active central nervous system malignancy . Patients prophylactic intrathecal intravenous chemotherapy central nervous system disease eligible . Patients significantly diseased obstruct gastrointestinal tract uncontrolled vomit diarrhea could interfere absorption KPT8602 . Prior exposure XPO1 inhibitor . Life expectancy ≥ 4 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>KPT-8602</keyword>
	<keyword>MM</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Relapsed/refractory Multiple Myeloma</keyword>
</DOC>